Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes

This study is testing a combination of two immune-modulating treatments — ciclosporin (an immune-suppressing drug) followed by low-dose IL-2 (a protein that boosts regulatory immune cells) — in people recently diagnosed with Type 1 diabetes. The goal is to slow or stop the immune system's attack on insulin-producing cells in the pancreas. **You may be eligible if...** - You are between 16 and 45 years old and have been diagnosed with Type 1 diabetes within the past 3 months - You have at least one positive diabetes autoantibody (e.g., anti-GAD, anti-islet) - You have not had diabetic ketoacidosis - Your insulin-producing cells are still partially functioning (measured by C-peptide levels) - You are willing to use effective contraception throughout the study **You may NOT be eligible if...** - You have signs of active infection - You have a documented history of clinical autoimmune disease - You have HIV, hepatitis B, or hepatitis C - You have a history of cancer (cured within the past 5 years) - You are pregnant or breastfeeding - You have chronic respiratory or heart disease - You have been on another clinical trial within the past 3 months Talk to your doctor to see if this trial is right for you.